AbbVie Inc. (ABBV) earnings date, results and what the price requires
NYSE · SEC CIK 0001551152 · SEC filings checked Oct 16, 2026
Previous results (SEC filings)
| Quarter ended | Reported | Revenue | Net income | Diluted EPS | Source |
|---|---|---|---|---|---|
| Jun 30, 2026 | Jul 31, 2026 | $16.99B | $3.61B | $2.03 | Filing |
| Mar 31, 2026 | Apr 29, 2026 | $15.00B | $695.0M | $0.39 | Filing |
| Dec 31, 2025 | Feb 4, 2026 | $16.62B | $1.82B | $1.02 | Filing |
| Sep 30, 2025 | Oct 31, 2025 | $15.78B | $186.0M | $0.10 | Filing |
| Jun 30, 2025 | Jul 31, 2025 | $15.42B | $938.0M | $0.52 | Filing |
| Mar 31, 2025 | Apr 25, 2025 | $13.34B | $1.29B | $0.72 | Filing |
| Dec 31, 2024 | Jan 31, 2025 | $15.10B | $-22.0M | $-0.02 | Filing |
| Sep 30, 2024 | Oct 30, 2024 | $14.46B | $1.56B | $0.88 | Filing |
What would AbbVie Inc. have to report for its valuation to change?
At $283.40, with a 9.0% required return and a 18× earnings multiple in 5 years, earnings per share must grow about 46.9% a year, to $24.22. On that path the next quarter needs diluted EPS near $0.15, against $0.10 in the quarter ended Sep 30, 2025.
Compare buying at the last close now with waiting for results: if the report moves the growth the price requires, the entry price you would accept changes with it.
| Result | Original | Yours |
|---|---|---|
| Required EPS growth / year | 46.9% | 46.9% |
| EPS needed in final year | $24.22 | $24.22 |
Changed: nothing yet. Model: EPS × (1+g)^years × final P/E, discounted at the required return, equals today's price. Inputs: SEC diluted EPS and the dated close above.
Prepare for earnings across my investments — $399/month
Keep working models for the companies you follow, compare your expectations with reported results, and review what changes your investment decision. ABBV goes in with your buy-or-wait comparison and assumptions preserved.
Figures come from SEC EDGAR XBRL filings. Dates marked "estimated" are calculated from the company's past results filings and are not confirmed. Not investment advice.